Market Place
Sourcing Support
atai`s Beckley Psytech Phase 1 Study Published
17 Apr 2024 //
GLOBENEWSWIRE
Beckley announces positive data from Ph IIa for Treatment Resistant Depression
27 Mar 2024 //
BUSINESSWIRE
atai Announces Positive Results from Beckley Phase 2a of BPL-003 in Depression
27 Mar 2024 //
GLOBENEWSWIRE
Beckley Retreats Research to Combat Veteran Suicide Through Psychedelic Retreats
13 Jul 2023 //
GLOBENEWSWIRE
First Patient Dosed in Beckley Psytech’s pH IIa Study of BPL-003
04 May 2023 //
BUSINESSWIRE
Beckley Psytech initiates Phase IIa study of 5-MeO-DMT candidate BPL-003
05 Apr 2023 //
BUSINESSWIRE
Beckley Psytech receives FDA IND approval for Phase IIb study of BPL-003
21 Feb 2023 //
BUSINESSWIRE
Beckley Psytech begins Phase IIa treatment resistant depression trial
22 Dec 2022 //
CLINICALTRIALSARENA
Beckley Successfully Completes Phase I Study of Lead Candidate BPL-003
14 Nov 2022 //
BUSINESSWIRE
Beckley Psytech Announces First Participant Dosed in Phase I Trial of ELE-101
09 Nov 2022 //
BUSINESSWIRE
Beckley Psytech doses first subject in Phase I trial of psychedelic compound
09 Nov 2022 //
CLINICALTRIALSARENA
Beckley Psytech to Attend & Present at Jefferies London Healthcare Conference
04 Nov 2022 //
BUSINESSWIRE
Beckley Psytech Strengthens Pipeline With Acquisition of Eleusis Therapeutics
24 Oct 2022 //
BUSINESSWIRE
Consolidation in psychedelics starts as Beckley and Eleusis combine
24 Oct 2022 //
PHARMAPHORUM
Beckley Psytech Announces Partnership With Ksana Health
14 Jun 2022 //
BUSINESSWIRE
Beckley Psytech Strengthens Leadership Team, Appoints Dr. Laura Trespidi as CDO
24 May 2022 //
BUSINESSWIRE
Beckley Psytech Announces Partnership With Empatica
18 May 2022 //
BUSINESSWIRE
Beckley Psytech Bolsters Pipeline of Next-Generation Psychedelic Medicines
11 May 2022 //
BUSINESSWIRE
Beckley Psytech to Attend and Present at 8th Annual LSX World Congress 2022
13 Apr 2022 //
BUSINESSWIRE
Beckley Psytech Begins Dosing in Healthy Volunteers in Phase 1 of 5-MeO-DMT
05 Apr 2022 //
BUSINESSWIRE
Beckley Psytech to Present at 32nd Annual Oppenheimer Healthcare Conference
09 Mar 2022 //
BUSINESSWIRE
Beckley Psytech`s First Cohort of Psychotherapists in TRD Phase 2 Trials
24 Jan 2022 //
BUSINESSWIRE
Beckley Psytech Announces First Cohort Dosed in Phase 1 Clinical Trial
25 Oct 2021 //
BUSINESSWIRE
Beckley Psytech announces first patient has received low-dose psilocybin
14 Sep 2021 //
PHARMIWEB
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.